Therapeutically, targeting CYP450 enzymes to restore redox balance or inhibiting B-cell receptor signalling (e.g., SYK blockade) may counteract disulfidoptosis resistance and enhance immune surveillance in HCC. Here, PPIB is linked to hepatocellular carcinoma.